Colo-rectal Cancer
Conditions
Keywords
colon cancer, rectal cancer, adjuvant therapy, PTC
Brief summary
The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the clinical prognosis, and explore the decision-making value and guiding significance of this technology in assisting the precise treatment of colorectal cancer. The completion of this study will provide real-world data support for the clinical application of micro tumor (PTC) in vitro 3D drug sensitivity detection technology, and provide more valuable reference basis for realizing the individualization and accuracy of colorectal cancer treatment and improving the clinical benefit rate.
Detailed description
The study is a multi agency prospective cohort study in China. The subjects were patients aged 18 \ 75 years with colorectal cancer diagnosed by histopathology or cytology. They must be colorectal cancer patients who have at least one assessable tumor focus, need adjuvant therapy after radical surgery, and have not received neoadjuvant therapy， ECoG physical condition score ≤ 2 points. And they must be voluntarily participate in and sign informed consent. The patients were randomly divided into PTC drug sensitivity test group and control group. The PTC drug sensitivity test group selected the adjuvant chemotherapy scheme according to the 3D drug sensitivity test results of micro tumor (PTC) in vitro. The control group made adjuvant chemotherapy strategy according to clinical experience. The primary endpoint was the non inferiority test, and the 3-year disease-free survival rate was T-C \>- Δ
Interventions
DRUGadjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro
Choose chemotherapeutic drugs（5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate） based on PTC drug sensitivity results.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18 \ 75 years old, regardless of gender 2. Patients with colorectal cancer diagnosed by histopathology or cytology 3. Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy 4. Having at least one assessable tumor focus 5. ECoG physical condition score ≤ 2 points 6. Voluntarily participate and sign informed consent
Exclusion criteria
1. Patients diagnosed with metastasis 2. Patients who cannot obtain tumor samples 3. Pregnant and lactating women 4. Patients with poor compliance 5. Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment 6. Patients with other malignant tumors 7. Suffering from serious mental and nervous system diseases 8. The researchers believe that patients should not be selected for this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Follow-up and record DFS of patients | 3 years after enrollment | We follow-up the patients by outpatient/telephone/online message to find out their survival situation and record their Disease-free-survival time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Follow-up and record TTP of patients | 3 years after enrollment | We follow-up the patients by outpatient/telephone/online message to find out their tumor situation and record their Time To Progress |
| Consistency between drug sensitivity results and clinical outcomes | 3 years after enrollment | Record the patient's PTC drug sensitivity results and the actual medication therapy, and record the patient's survival status through telephone follow-up, online follow-up and offline diagnosis to compare whether there is correlation between them. |
| Follow-up and record ORR of patients | 3 years after enrollment | We follow-up the patients by outpatient/telephone/online message to find out their tumor situation and record their Objective Response Rate |
| Follow-up and record PFS of patients | 3 years after enrollment | We follow-up the patients by outpatient/telephone/online message to find out their tumor situation and record their Progress Free Survival time |
| Follow-up and record OS of patients | 3 years after enrollment | We follow-up the patients by outpatient/telephone/online message to find out their tumor and survival situation and record their Overall Survival time |
Countries
China
Contacts
Primary ContactJiaolin Zhou, Professor
Outcome results
None listed